drugset / Trial / NCT02321748
Drug-Drug Interaction Study: ASP2151 and Montelukast
RandomizedCrossoverOpen-labelOther
Summary
CYP2C8 is involved in the metabolism of many drugs. So, it is important to assess in vivo the inhibitory effect of ASP2151 on that enzyme to determine any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP2C8 probe substrate montelukast.
Timeline
- Start
- 2014-12
- Primary completion
- 2015-04
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amenamevir | Small molecule | 400 mg | — |
| Subject | Montelukast | Other / unclassified | 10 mg | — |
Indications
No indication recorded.